{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:39Z","timestamp":1772119419330,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uncontrolled diabetes mellitus (DM) accelerates atherosclerosis and vascular diseases, leading to micro- and macrovascular complications. Early cardiac and kidney involvement necessitates an early biomarker. Sclerostin is a Wnt-signaling inhibitor, having a pathophysiological role in vasculopathy, and could be used as a vasculopathy marker. Nevertheless, few data are available in pediatric patients with type 1 diabetes mellitus (T1DM). We aimed at assessing its serum level, and relation to diabetic microvascular and macrovascular complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a case control study on patients with T1DM, and healthy controls. Patients were divided into non-diabetic nephropathy (DN), and DN groups according to proteinuria. Patients\u2019 clinicodemographic and anthropometrics were obtained, with withdrawal of fasting serum lipid profile, kidney function test, and serum sclerostin. Carotid intimal media thickness (CIMT), a marker of subclinical atherosclerosis, was measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We had 75 comparable subjects, where median (IQR) serum sclerostin levels were significantly higher in DN, compared to non-DN and controls [90.83 (82.32 \u2013 115.1), vs. 33.29 (28.37 \u2013 38.53), vs. 13.5 (10.32 \u2013 15.72) ng\/mL,respectively, p,\u2009&lt;\u20090.001]. Similarly, median (IQR) CIMT was significantly higher in DN, than in non-DN and controls [1.1 (0.8 \u2013 1.3), vs. 0.11 (0.1 \u2013 0.2), vs. 0.11 (0.1 \u2013 0.2) mm, respectively, p\u2009&lt;\u20090.001]. Serum sclerostin level correlated positively with disease duration, higher HgbA1c%, albuminuria level, and CIMT in all patients. The cut-off values of serum sclerostin\u2009&gt;\u200960.0\u00a0ng\/mL and CIMT\u2009&gt;\u20090.3\u00a0mm were able to detect DN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum sclerostin levels may serve as a potential biomarker for microvascular and macrovascular complications in pediatric patients with T1DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-06793-3","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:31:51Z","timestamp":1747017111000},"page":"3155-3162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum sclerostin as a marker of microvascular and macrovascular complications among children and adolescents with type 1 diabetes mellitus"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4684-229X","authenticated-orcid":false,"given":"Dina E.","family":"Sallam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine Ibrahim Mahmoud","family":"Elhenawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya Mohamed Abdullah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Ibrahim Abdelfattah","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Mohamed","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"6793_CR1","doi-asserted-by":"publisher","unstructured":"Sagoo MK, Gnudi L (2020) Diabetic Nephropathy. An Overview. In Gnudi L, Long D (eds) Diabetic Nephropathy. Methods in Molecular Biology, vol 2067. Humana, New York, NY. https:\/\/doi.org\/10.1007\/978-1-4939-9841-8_1","DOI":"10.1007\/978-1-4939-9841-8_1"},{"key":"6793_CR2","doi-asserted-by":"publisher","first-page":"F831","DOI":"10.1152\/ajprenal.00313.2016","volume":"311","author":"CB Marshall","year":"2016","unstructured":"Marshall CB (2016) Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol 311:F831\u2013F843. https:\/\/doi.org\/10.1152\/ajprenal.00313.2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"6793_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00467-014-2796-5","volume":"30","author":"M Afkarian","year":"2015","unstructured":"Afkarian M (2015) Diabetic kidney disease in children and adolescents. Pediatr Nephrol 30:65\u201371. https:\/\/doi.org\/10.1007\/s00467-014-2796-5","journal-title":"Pediatr Nephrol"},{"key":"6793_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2213-8587(18)30035-4","volume":"6","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, Donaghue KC, Maahs DM (2018) Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment? Lancet Diabetes Endocrinol 6:809\u2013820. https:\/\/doi.org\/10.1016\/S2213-8587(18)30035-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6793_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41574-019-0198-2","volume":"15","author":"ML Marcovecchio","year":"2019","unstructured":"Marcovecchio ML, Dalton RN, Daneman D, Deanfield J, Jones TW, Neil HAW, Dunger DB (2019) A new strategy for vascular complications in young people with type 1 diabetes mellitus. Nat Rev Endocrinol 15:429\u2013435. https:\/\/doi.org\/10.1038\/s41574-019-0198-2","journal-title":"Nat Rev Endocrinol"},{"key":"6793_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2014.12.029","volume":"238","author":"R Dalla Pozza","year":"2015","unstructured":"Dalla Pozza R, Ehringer-Schetitska D, Fritsch P, Jokinen E, Petropoulos A, Oberhoffer R (2015) Intima media thickness measurement in children: A statement from the Association for European Paediatric Cardiology (AEPC) working group on cardiovascular prevention endorsed by the association for European paediatric cardiology. Atherosclerosis 238:380\u2013387. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.029","journal-title":"Atherosclerosis"},{"key":"6793_CR7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/pedi.13019","volume":"21","author":"NA Salem","year":"2020","unstructured":"Salem NA, El Helaly RM, Ali IM, Ebrahim HAA, Alayooti MM, El Domiaty HA, Aboelenin HM (2020) Urinary Cyclophilin A and serum Cystatin C as biomarkers for diabetic nephropathy in children with type 1 diabetes. Pediatr Diabetes 21:846\u2013855. https:\/\/doi.org\/10.1111\/pedi.13019","journal-title":"Pediatr Diabetes"},{"key":"6793_CR8","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.3390\/ijms21134779","volume":"21","author":"A Catalano","year":"2020","unstructured":"Catalano A, Bellone F, Morabito N, Corica F (2020) Sclerostin and Vascular Pathophysiology. Int J Mol Sci 21:4779. https:\/\/doi.org\/10.3390\/ijms21134779","journal-title":"Int J Mol Sci"},{"key":"6793_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jdiacomp.2019.04.012","volume":"33","author":"MAM Shalash","year":"2019","unstructured":"Shalash MAM, Rohoma KH, Kandil NS, Abdel Mohsen MA, Taha AAF (2019) Serum sclerostin level and its relation to subclinical atherosclerosis in subjects with type 2 diabetes. J Diabetes Complications 33:592\u2013597. https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.04.012","journal-title":"J Diabetes Complications"},{"key":"6793_CR10","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/pedi.13454","volume":"23","author":"I Libman","year":"2022","unstructured":"Libman I, Haynes A, Lyons S, Pradeep P, Rwagasor E, Tung JY, Jefferies CA, Oram RA, Dabelea D, Craig ME (2022) ISPAD clinical practice consensus guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 23:1160\u20131174. https:\/\/doi.org\/10.1111\/pedi.13454","journal-title":"Pediatr Diabetes"},{"key":"6793_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"6793_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1681\/ASN.V1341034","volume":"13","author":"HJ Mattix","year":"2002","unstructured":"Mattix HJ, Hsu CY, Shaykevich S, Curhan G (2002) Use of the albumin\/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 13:1034\u20131039. https:\/\/doi.org\/10.1681\/ASN.V1341034","journal-title":"J Am Soc Nephrol"},{"key":"6793_CR13","doi-asserted-by":"publisher","first-page":"E1159","DOI":"10.1210\/jc.2011-0254","volume":"96","author":"M McNulty","year":"2011","unstructured":"McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R (2011) Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 96:E1159\u2013E1162. https:\/\/doi.org\/10.1210\/jc.2011-0254","journal-title":"J Clin Endocrinol Metab"},{"key":"6793_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000343145","volume":"34","author":"PJ Touboul","year":"2012","unstructured":"Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS (2012) Mannheim carotid intima-media thickness and plaque consensus (2004\u20132006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34:290\u2013296. https:\/\/doi.org\/10.1159\/000343145","journal-title":"Cerebrovasc Dis"},{"key":"6793_CR15","first-page":"39","volume":"50","author":"S Ishikawa","year":"2023","unstructured":"Ishikawa S, Takahashi I, Takahashi T (2023) Serum sclerostin levels in children and adolescents with type 1 diabetes mellitus. Akita Igaku 50:39\u201348","journal-title":"Akita Igaku"},{"key":"6793_CR16","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2016-2371","volume":"102","author":"MF Faienza","year":"2017","unstructured":"Faienza MF, Ventura A, Delvecchio M, Fusillo A, Piacente L, Aceto G, Colaianni G, Colucci S, Cavallo L, Grano M, Brunetti G (2017) High Sclerostin and Dickkopf-1 (DKK-1) serum levels in children and adolescents with Type 1 diabetes mellitus. J Clin Endocrinol Metab 102:1174\u20131181. https:\/\/doi.org\/10.1210\/jc.2016-2371","journal-title":"J Clin Endocrinol Metab"},{"key":"6793_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00198-016-3802-5","volume":"28","author":"C Tsentidis","year":"2017","unstructured":"Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K (2017) Increased levels of Dickkopf-1 are indicative of Wnt\/\u03b2-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density. Osteoporos Int 28:945\u2013953. https:\/\/doi.org\/10.1007\/s00198-016-3802-5","journal-title":"Osteoporos Int"},{"key":"6793_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bone.2018.07.021","volume":"120","author":"A W\u0119drychowicz","year":"2019","unstructured":"W\u0119drychowicz A, Sztefko K, Starzyk JB (2019) Sclerostin and its association with insulin resistance in children and adolescents. Bone 120:232\u2013238. https:\/\/doi.org\/10.1016\/j.bone.2018.07.021","journal-title":"Bone"},{"key":"6793_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","volume":"97","author":"A Garc\u00eda-Mart\u00edn","year":"2012","unstructured":"Garc\u00eda-Mart\u00edn A, Rozas-Moreno P, Reyes-Garc\u00eda R, Morales-Santana S, Garc\u00eda-Fontana B, Garc\u00eda-Salcedo JA, Mu\u00f1oz-Torres M (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234\u2013241. https:\/\/doi.org\/10.1210\/jc.2011-2186","journal-title":"J Clin Endocrinol Metab"},{"key":"6793_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2337\/diabetes.55.02.06.db05-1103","volume":"55","author":"M Nieuwdorp","year":"2006","unstructured":"Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H, Kastelein JJ, Stroes ES (2006) Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 55:480\u2013486. https:\/\/doi.org\/10.2337\/diabetes.55.02.06.db05-1103","journal-title":"Diabetes"},{"key":"6793_CR21","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1681\/ASN.2015091070","volume":"27","author":"M Garsen","year":"2016","unstructured":"Garsen M, Lenoir O, Rops AL, Dijkman HB, Willemsen B, van Kuppevelt TH, Rabelink TJ, Berden JH, Tharaux PL, van der Vlag J (2016) Endothelin-1 induces proteinuria by Heparanase-mediated disruption of the glomerular Glycocalyx. J Am Soc Nephrol 27:3545\u20133551. https:\/\/doi.org\/10.1681\/ASN.2015091070","journal-title":"J Am Soc Nephrol"},{"key":"6793_CR22","first-page":"317","volume":"22","author":"R Koos","year":"2013","unstructured":"Koos R, Brandenburg V, Mahnken AH, Schneider R, Dohmen G, Autschbach R, Marx N, Kramann R (2013) Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 22:317\u2013325","journal-title":"J Heart Valve Dis"},{"key":"6793_CR23","doi-asserted-by":"publisher","first-page":"e3069","DOI":"10.1002\/dmrr.3069","volume":"35","author":"G Leto","year":"2019","unstructured":"Leto G, D\u2019Onofrio L, Lucantoni F, Zampetti S, Campagna G, Foffi C, Moretti C, Carlone A, Palermo A, Leopizzi M, Porta N, Massucci M, Lenzi A, Bertoletti GB, Rocca CD, Buzzetti R (2019) Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy. Diabetes Metab Res Rev 35:e3069","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06793-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:36:09Z","timestamp":1757169369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06793-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6793"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06793-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5734283\/v1","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This manuscript has been posted on a nonprofit preprint server.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}